medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2009, Number 5

<< Back Next >>

Rev Mex Urol 2009; 69 (5)

3-nitrotyrosine (3-NT) determination in tissues with prostate cancer and benign prostatic hyperplasia

Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Zapata-Villalba MA, Flores-Terraza JE, Torres-Salazar JJ

Language: Spanish
References: 20
Page: 224-230
PDF size: 2139.08 Kb.


ABSTRACT

Recent reports have placed prostate cancer (CaP) as the third cause of death by cancer in the world and as the principal cause in Mexico after skin cancer. The role of oxidative stress has been observed in cancer etiology. Due to the elevated incidence of prostate cancer in the Mexican population, it is of vital importance to contribute to the development of new hypotheses resulting in more complex studies and in this way increasing the probability of developing molecular markers for diagnosing cancer.
Objective: To evaluate the existence of any alteration in levels of 3-nitrotyrosine (3-NT), an oxidative stress marker, in prostate cancer and benign prostatic hyperplasia.
Materials and methods: Thirty benign prostatic hyperplasia tissue samples and forty prostate cancer tissue samples were obtained and conditions were standardized to immunohistochemically detect the presence of 3-nitrotyrosine in tissue.
Results: The percentages of immunoreactive 3-nitrotyrosine were 25.78% in prostate cancer tissue and 4.43% in benign prostatic hyperplasia tissue.
Conclusions: Densitometric data of 3-NT immunoreactivity in prostate cancer tissue were higher than those obtained in benign prostatic hyperplasia tissue, suggesting that 3-NT determination could be used as a tumor marker.


REFERENCES

  1. Hall SE, Holman CD, Wisniewski ZS, Semmens J. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int 2005;95(1):51-8.

  2. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. Boca Raton, Florid. CRC Press, 1997.

  3. Manual de Oncología. Instituto Nacional de Cancerología. México: McGraw-Hill, 2003.

  4. Guess HA. Benign prostatic Hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14:131-53.

  5. Thorpe A, Neal D. Benign Prostatic Hyperplasia. Lancet 2003; 361(9366):1359-67.

  6. Sarmina Y, Resnick MI. Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989; 141(4):866-9.

  7. Barry MJ. Epidemiology and Natural History of benign prostatic hyperplasia. Urol Clin North Am 1990; 17(3):495-507.

  8. de Marzo A. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160(6 Pt 2):2381-92.

  9. Hennekens CH. Antioxidant Vitamins and Cancer. Am J Med 1994; 97(3A):2S-4S.

  10. Cascales-Angosto M. Estallido respiratorio de los fagocitos. An Real Acad Nac Farm 2005; 42:365-86.

  11. Garcia TB. NADPH fagocítica: componentes, ensamblaje y mecanismo de acción. Rev Cubana Invest Bioméd 2001; 20:59-63.

  12. Hurtado-Bredda FJ. Estrés oxidativo y nitrosativo en la sepsis. Med Inten 2005; 29:159-165.

  13. Pacheco-Ramírez MA, Rodríguez-Perales MA, López-Chavira A, Canal-Andrade LP, et al. Expresión de las sintasas de óxido nítrico en tumores glómicos de cabeza y cuello. Rev Sanid Milit 2006; 60:369-378.

  14. Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, Erzurum SC, Aulak KS. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 2005:172(5): 597-605.

  15. Terry DO. Oxidative Damage and Cancer. Amer J Path 2002; 160: 403-408.

  16. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998;82(10):1897-903.

  17. Maragoni K, Neves AF, Cardoso AM, Santos WK, Faria PC. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Dtect Prev 2006; 30(1):7-13.

  18. Diaz Arce D. Óxido nítrico, mutagénesis y cáncer. Rev Cubana Inves Bioméd 2004:23:184-189.

  19. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W. Nitric oxide mediated inhibition of androgen recerptor activity; possible implications for prostate cancer progression. Oncogene 2007; 22;26(13).

  20. Baltaci S, Orhan D, Gögüs C, Türkölmez K, Tulunay O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low and high grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2001;88(1):100-3.




2020     |     www.medigraphic.com